

The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors

Erratum

In the article, “The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors”,^[1] which appears in Volume 101, Issue 3 of *Medicine*, the incorrect figure appeared for figure 5. The correct figure is:




Figure 5. Sensitivity analysis of the relationship between PLR and survival outcomes in NSCLC patients treated with ICIs. (A) Sensitivity analysis of OS shows that the research of Russo, Takada1, Dusselier is the main source of heterogeneity; (B) Sensitivity analysis of PFS shows that the research of Takada and Xiong is the main source of heterogeneity. Abbreviations: PLR, the ratio of platelets to lymphocytes; non-small cell lung cancer, non-small cell lung cancer; ICIs: immune checkpoint inhibitors; OS, overall survival rate; PFS, progression-free survival

The authors have no funding and conflicts of interest to disclose.

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

Received: 27 September 2022 / Accepted: 27 September 2022

<http://dx.doi.org/10.1097/MD.00000000000031359>




Figure 5. Continued

Reference:

- [1] Liu N, Mai J, Tao P. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. *Medicine.* 2022;101:e 28617.